Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis

The authors have informed the Publisher that [Fig. 1] has incorrect information in the above-mentioned article published online on June 28, 2021. DOI of the article is 10.1055/s-0041-1729973. The correct image is presented below.

Fig. 1 The clinical outcome of off-Nuc (nucleos(t)ide analogues) therapy in 308 hepatitis B e antigen negative chronic hepatitis B patients with hepatitis B virus (HBV)–cirrhosis. Sustained response is defined as persistent HBV DNA ≤ 2000 IU/mL accompanied with normal alanine aminotransferase (ALT) level. Virological relapse is defined as HBV DNA > 2000IU/mL and clinical relapse stands for HBV DNA > 2000 IU/mL along with ALT > 2x upper limit of normal. Retreatment decision is made by joint physicians/patients' decision in addition to the reimbursement policy. Patients with sustained response and no retreatment had the highest hepatitis B surface antigen (HBsAg) loss rate (10 of 65, 15.4%) followed by those without clinical relapse nor retreatment (15 of 101, 14.9%) and those with clinical relapse who were not retreated (11 of 141, 7.8%). Only three patients in the retreated arm showed HBsAg loss. ACLF, acute on chronic liver failure; Retx, retreatment.

Publikationsverlauf

Artikel online veröffentlicht:
01. Oktober 2021